Tag - ORMP


Cantor starts Oramed at OW; PT $20

Cantor Fitzgerald launched coverage of Oramed Pharmaceuticals (NASDAQ:ORMP) with an “overweight” rating and price target of $20. The stock closed at $10.63 on Feb. 17. Oramed is a developing novel drug formulations for...


Oramed initiates Phase 3 oral insulin trials

Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) began screening patients for its two Phase 3 trials evaluating ORMD-0801 for the treatment of Type 2 diabetes. The trials will enroll a total of 1,125 Type 2 diabetes patients...

Oramed sees value creating events through 2016

Oramed Pharmaceuticals’ (NASDAQ:ORMP) oral insulin development program has multiple value-creating events in the works through 2016. They include completion of an ongoing Phase 2b FDA multi-site study for oral insulin...